Amendments to the Claims

The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound represented by the structural formula

Formula III

wherein:

R is selected from the group consisting of alkyl, CF_3, cycloalkyl, cycloalkylalkyl, arylalkyl, and $-C(O)R^7$, wherein each of said alkyl, arylalkyl, and cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF_3, CN, $-OCF_3$, $-OR^6$, $-C(O)R^7$, $-NR^5R^6$, $-C(O_2)R^6$, $-C(O)NR^5R^6$, $-(CHR^5)_nOR^6$, $-SR^6$, $-S(O_2)R^7$, $-S(O_2)NR^5R^6$, $-N(R^5)S(O_2)R^7$, $-N(R^5)C(O)R^7$ and $-N(R^5)C(O)NR^5R^6$;

R^1 is H, halogen or alkyl;

R^2 is selected from the group consisting of H, halogen, CN, cycloalkyl, heterocyclyl, alkynyl and $-CF_3$;

R^3 is selected from the group consisting of aryl (with the exception of phenyl), heteroaryl (with the exception of furyl), heterocyclyl, $-(CHR^5)_n$-heteroaryl, $-S(O_2)R^6$, $-C(O)R^6$, $-S(O_2)NR^5R^6$, $-C(O)OR^6$, $-C(O)NR^5R^6$,  ,  , and  , wherein each of said aryl, heteroaryl and heterocyclyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF_3, CN, $-OCF_3$, $-OR^5$, $-NR^5R^6$, $-C(O_2)R^5$,

$-C(O)NR^5R^6$, $-SR^6$, $-S(O_2)R^6$, $-S(O_2)NR^5R^6$, $-N(R^5)S(O_2)R^7$, $-N(R^5)C(O)R^7$ and $-N(R^5)C(O)NR^5R^6$, with the proviso that when R^3 is $-(CHR^5)_n$-heteroaryl, R^2 can additionally be alkyl;

R^5 is H or alkyl;

R^6 is selected from the group consisting of H, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF_3, OCF_3, CN, $-OR^5$, $-NR^5R^6$, $-CH_2OR^5$, $-C(O_2)R^5$, $-C(O)NR^5R^6$, $-SR^6$, $-S(O_2)R^7$, $-S(O_2)NR^5R^6$, $-N(R^5)S(O_2)R^7$, $-N(R^5)C(O)R^7$ and $-N(R^5)C(O)NR^5R^6$;

R^7 is selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF_3, OCF_3, CN, $-OR^5$, $-NR^5R^6$, $-CH_2OR^5$, $-C(O_2)R^5$, $-C(O)NR^5R^6$, $-SR^6$, $-S(O_2)R^7$, $-S(O_2)NR^5R^6$, $-N(R^5)S(O_2)R^7$, $-N(R^5)C(O)R^7$ and $-N(R^5)C(O)NR^5R^6$;

R^8 is selected from the group consisting of R^6, $-C(O)NR^5R^6$, $-S(O_2)NR^5R^6$, $-C(O)R^7$, $-C(O_2)R^6$, $-S(O_2)R^7$ and $-(CH_2)$-aryl;

m is 0 to 4; and

n is 1-4.

Claim 2 (currently amended): The compound of claim 1, wherein R is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl and arylalkyl, wherein each of said alkyl, cycloalkyl, and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF_3, CN, $-OCF_3$, $-OR^6$, $-C(O)R^7$, $-NR^5R^6$, $-C(O_2)R^6$, $-C(O)NR^5R^6$, $-SR^6$, $-S(O_2)R^7$, $-S(O_2)NR^5R^6$, $-N(R^5)S(O_2)R^7$, $-N(R^5)C(O)R^7$ and $-N(R^5)C(O)NR^5R^6$[.] ;

R^1 is H or halogen;

R^2 is selected from the group consisting of H, halogen, cycloalkyl, CN, alkynyl and $-CF_3$;

R^3 is selected from the group consisting of aryl, heteroaryl, heterocyclyl, $-(CHR^5)_n$-heteroaryl, $-S(O_2)R^6$, $-C(O)R^6$, $-S(O_2)NR^5R^6$, $-C(O)OR^6$, $-C(O)NR^5R^6$,  ,  , wherein each of said aryl, heteroaryl and heterocyclyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF_3, CN, $-OCF_3$, $-N(R^5)C(O)R^7$, $-C(O)NR^5R^6$, $-S(O_2)R^6$, and $-N(R^5)C(O)R^7$;

R^5 is H or lower alkyl;

m is 0 to 2; and

n is 1 to 3.

Claim 3 (original): The compound of claim 2, wherein R is alkyl, arylalkyl or cycloalkylalkyl.

Claim 4 (original): The compound of claim 3, wherein R is selected from the group consisting of methyl, ethyl, t-butyl, cyclohexylmethyl, benzyl and phenethyl.

Claim 5 (original): The compound of claim 2, wherein R^1 is H.

Claim 6 (original): The compound of claim 2, wherein R^1 is methyl.

Claim 7 (original): The compound of claim 2, wherein R^2 is H, F, Cl, Br or I.

Claim 8 (original): The compound of claim 7, wherein R^2 is Br.

Claim 9 (original): The compound of claim 8, wherein R^3 is (pyrid-2-yl)methyl, (pyrid-3-yl)methyl, (pyrid-4-yl)methyl, thien-2-yl or thien-3yl, wherein said pyridyl and thienyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of F, Cl, Br, CF_3, lower alkyl, methoxy and CN.

Claim 10 (original): The compound of claim 9, wherein R^3 is (pyrid-2-yl)methyl.

Claim 11 (original): The compound of claim 9, wherein R^3 is (pyrid-3-yl)methyl.

Claim 12 (original): The compound of claim 9, wherein R^3 is (pyrid-4-yl)methyl.

Claim 13 (original): The compound of claim 2, wherein m is 0.

Claim 14 (original): The compound of claim 2, wherein n is 1.

Claim 15 (currently amended): A compound of the formula:



or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 16 (currently amended): A method of inhibiting ~~one or more cyclin dependent kinases~~ cyclin dependent kinase 2 ("CDK2"), comprising administering a therapeutically effective amount of at least one compound of claim 1 to a patient in need of such inhibition.

Claims 17-24: Cancelled.

Claim 25 (original): A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

Claim 26 (original): The pharmaceutical composition of claim 25, additionally comprising one or more anti-cancer agents selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 27 (original): A compound of claim 1 in purified form.